Study of HSK41959 plus standard therapy for solid tumors with MTAP loss
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called HSK41959 combined with standard cancer treatment for people with solid tumors that lack a gene called MTAP. It may help if your tumor has this specific genetic change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are well enough to be up and about at least half the day (ECOG 0 or 1).
- Your tumor has been tested and found to be missing the MTAP gene.
- You have at least one tumor that can be measured on a scan.
- You have not had prior treatment with drugs targeting MAT2A or PRMT5 pathways.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called CS08399 in people with advanced or hard-to-treat cancers (solid tumors or lymphoma) that have a specific genetic change called MTAP deletion. The drug may help slow or stop cancer growth in people whose cancers no longer respond to standard treatments.
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.